MINNEAPOLIS, May 10 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, Uroplasty’s President and CEO, and Medi Jiwani, Uroplasty’s Vice President and CFO, will present the Company’s business strategy and financial results at the MDB Capital Bright Lights Conference at 10:30 AM PDT on Wednesday, May 12, 2010 at The Palace Hotel in San Francisco.
Attendance at the conference is by invitation only. A live audio-only webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at http://www.wsw.com/webcast/mdb/upi/, or through Uroplastys website at www.uroplasty.com. A link to the archived presentation will be available on the Uroplasty website.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the continued commercialization of our Urgent® PC system, which we believe is the only FDA-approved minimally invasive neuromodulation device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence - symptoms often associated with overactive bladder. We also offer Macroplastique®, an injectable bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. Please visit Uroplasty, Inc. at http://uroplasty.com.
For Further Information: Uroplasty, Inc. David Kaysen, President and CEO, or Medi Jiwani, Vice President, CFO, Treasurer 952.426.6140 | EVC Group Doug Sherk (Investors), 415.896.6820 Chris Gale (Media), 646.201.5431 | |
SOURCE Uroplasty, Inc.
